Hyperstable Serum Albumin Variants for Microbial Mass Production

  • Yeda
  • From Israel
  • Responsive
  • Patents for licensing

Summary of the technology

Serum albumins are essential in a wide variety of molecular and cellular applications, including in the medical, biotechnological and cultivated meat industries. Albumins, however, are currently sourced from animal serum, raising significant concerns about reproducibility, scalability, and ethics. To address these issues, Prof. Fleishman and his team have designed and validated improved and boiling-resistant serum albumin variants that can be efficiently produced by bacteria.

Yeda

Background and Unmet Need

Albumins derived from animal or human plasma present ethical and reproducibility challenges (e.g., contamination
risks, batch-to-batch variability, and animal welfare). Additionally, the growing demand for serum albumin in the
cultivated meat industry far exceeds the current production capacity of recombinant proteins. While yeast-based
production has been explored, it remains complex. In contrast, bacterial production offers advantages in terms of
speed, cost, and efficiency, but the complex structure of albumin has precluded its heterologous production, until
now.

The Solution

Computationally designed hyperstable variants of mammalian serum albumins readily expressed and purified from E. coli.

Technology Essence
Using the PROSS computational platform, stable designs of human and bovine serum albumins (HSA and BSA)
were developed, exhibiting superior thermal stability compared to plasma-derived counterparts, of up to 40°C and
even beyond the boiling point. The optimized designs were robustly expressed in E. coli in 100s of mg/l culture in
standard lab settings. By contrast, the natural albumins did not express solubly. The engineered HSA and BSA
variants were not toxic to HEK293T and hybridoma cells, carried typical small-molecule ligands of albumins and
exhibited potent activity in restriction enzyme reactions, thus enabling applications in cell culture, and molecular
biology (Figure 1).
Figure 1. Stabilized HSA and BSA designs with improved thermal properties, generated through computational
modeling for cell culture, and biotech applications.

Applications and Advantages

  • Fast and economical large-scale production of animal-free reagents
  • Applicable to cultivated meat, cell culture and molecular biology applications
  • Significantly higher thermal stability, enabling direct purification from bacteria by boiling

Development Status

All tested stabilized variants were highly expressed in E. coli and their functional properties were validated in cell
culture and in vitro applications.

Related Keywords

  • Biological Sciences
  • Stem cell Technologies
  • Microbiology Technology
  • Protein Engineering
  • Agriculture and Marine Resources
  • Agrofood Industry
  • Food Microbiology / Toxicology / Quality Control
  • Industrial Products
  • bacteria
  • cells
  • alternative meat

About Yeda

Yeda ("Knowledge" in Hebrew) Research and Development Company Ltd. is the commercial arm of the Weizmann Institute of Science (WIS) and is the second company of its kind established in the world.

WIS is one of the world’s leading multidisciplinary basic research institutions in the natural and exact sciences. It is located in Rehovot, Israel, just south of Tel Aviv. It was initially established as the Daniel Sieff Institute in 1934, by Israel and Rebecca Sieff of London in memory of their son Daniel. In 1949, it was renamed for Dr. Chaim Weizmann, the first President of the State of Israel and Founder of the Institute.

Yeda initiates and promotes the transfer to the global marketplace of research findings and innovative technologies developed by WIS scientists. Yeda holds an exclusive agreement with WIS to market and commercialize its intellectual property and generate income to support further research and education.

Since 1959 Yeda has generated the highest income per researcher compared to any other TTO worldwide. Weizmann has generated a number of groundbreaking therapies, such as Copaxone, Rebif, Tookad, Erbitux, Vectibix, Protrazza, Humira, and recently the CAR-T cancer therapy Yescarta.

Yeda performs the following activities:

◣ Identifies and assesses research projects with commercial potential.
◣ Protects the intellectual property of WIS and its scientists.
◣ Licenses WIS' inventions and technologies to industry.
◣ Establishes new Startup companies based in WIS Intellectual Property
◣ Channels funding from industry to research projects.

Our portfolio covers a broad spectrum of the natural sciences, including:

◣ Agriculture and Plant Genetics, including Bio-fuels
◣ Chemistry and Nanotechnology
◣ Environmental Sciences and Solar Energy
◣ Mathematics and Computer Science
◣ Medical Devices
◣ Pharmaceuticals and Diagnostics
◣ Physics and Electro-Optics
◣ Research Tools

Yeda

Never miss an update from Yeda

Create your free account to connect with Yeda and thousands of other innovative organizations and professionals worldwide

Yeda

Send a request for information
to Yeda

About Technology Offers

Technology Offers on Innoget are directly posted
and managed by its members as well as evaluation of requests for information. Innoget is the trusted open innovation and science network aimed at directly connect industry needs with professionals online.

Help

Need help requesting additional information or have questions regarding this Technology Offer?
Contact Innoget support